JLM based Entera Bio Raising $10m at $94m Valuation
Sept 13, 2017 – Entera is developing a drug for the treatment of osteoporosis. After announcing its general plan for a Nasdaq IPO, as well
BiondVax to Manufacture its Universal Flu Vaccine in Jerusalem!
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) signed a lease agreement for a commercial facility in Jerusalem to manufacture its universal flu vaccine. BiondVax Pharmaceuticals Ltd. also announced in
CellCure Invites the Public toJoin NeuroScience’s Clinical Trial To Treat Dry Age-Related Macular Degeneration
If you are over 50, and suffer from dry AMD (dry form, age-related macular degeneration), you may be eligible to join our clinical trial using
BrainsWay’s Backlog Revenues Due to Future Lease Agreements Increased 27% to $19 Million
Aug 22 2017 – Jerusalem based Brainsway Ltd. (TASE:BRIN), a leader in the advanced non-invasive treatment of brain disorders, announced the Company’s financial results for
New drug-testing technology from the Hebrew University could drastically cut animal testing
Aug 22 – Prof Yakov Nahmias’s human-on-a-chip platform has the unique ability to predict risk of toxicity in pharma and cosmetic product candidates without animal
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
August 21, 2017 — The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic
Automatic Accurate Method for Measuring Blood Pressure Developed by Lev Academic Center (Jerusalem College of Technology)
Aug 12, 2017 – Automatic blood pressure devices are often used to assess blood pressure levels at home and in the clinic. But these devices
HIL Applied Medical names Reno, Nevada its North American headquarters after University Collaboration
Aug 4, 2017 A continuing collaboration between Jerusalem-based HIL Applied Medical and the University of Nevada, Reno has led to the Israeli-based company naming Reno
Oramed: On To Phase III And The Tel Aviv Stock Exchange
Aug 9 2017 – Oral Insulin Can Change the Diabetes Market Fundamentally and right now the company closest to succeeding in this endeavor is Oramed Pharmaceuticals (ORMP).
